Liquid biopsy is a promising tool to predict benefit from anti–epidermal growth factor receptor (EGFR) retreatment in metastatic colorectal cancer patients. However, this technique is far from ready for routine clinical practice. Therefore, we identified 86 patients in a real-life database of 5530 patients to explore clinical features expected to predict benefit from anti-EGFR retreatment; however, none of these factors was predictive of response to anti-EGFR retreatment.

Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis

Scartozzi M.;
2020-01-01

Abstract

Liquid biopsy is a promising tool to predict benefit from anti–epidermal growth factor receptor (EGFR) retreatment in metastatic colorectal cancer patients. However, this technique is far from ready for routine clinical practice. Therefore, we identified 86 patients in a real-life database of 5530 patients to explore clinical features expected to predict benefit from anti-EGFR retreatment; however, none of these factors was predictive of response to anti-EGFR retreatment.
2020
Chemorefractory metastatic colorectal cancer; Circulating tumor DNA; Liquid biopsy; Rechallenge; Resistance and sensitivity to anti-EGFR
File in questo prodotto:
File Dimensione Formato  
rossini2020.pdf

Solo gestori archivio

Tipologia: versione post-print
Dimensione 518.76 kB
Formato Adobe PDF
518.76 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/296878
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 20
social impact